drugset
drugset / Trial / NCT02161185

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

NCT02161185 ↗

Phase 3 Terminated 7 enrolled UCB Biopharma S.P.R.L.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.

Timeline

Start
2014-05
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 5 mg Intranasal

Indications

epilepsy